<DOC>
	<DOC>NCT00279734</DOC>
	<brief_summary>Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.</brief_summary>
	<brief_title>Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Healthy Subjects Body Weight between 60 and 100 kg. Males and Females must be using adequate contraceptive methods during study and for 10 weeks after dose of study mediciation. Females who are prgnant or breastfeeding History of autoimmune disorder, immunodeficiency, or infection within past 3 months. Active TB requiring treatment within the previous 3 years. Positive breast cancer screen, PPD test. Vaccination with tetanus or pneumococcal vaccine within 5 years. Vaccination with any live vaccine within 4 weeks. History of drug or alcohol abuse. Any significant allergy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>